Bicara Therapeutics Common Stock Buy Hold or Sell Recommendation
| BCAX Stock | 20.96 0.51 2.49% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Bicara Therapeutics Common is 'Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Bicara Therapeutics Common given historical horizon and risk tolerance towards Bicara Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Bicara Therapeutics Common, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Bicara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Bicara and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Bicara Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Bicara |
Execute Bicara Therapeutics Buy or Sell Advice
The Bicara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bicara Therapeutics Common. Macroaxis does not own or have any residual interests in Bicara Therapeutics Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bicara Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Modest | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Bicara Therapeutics Trading Alerts and Improvement Suggestions
| Bicara Therapeutics had very high historical volatility over the last 90 days | |
| Bicara Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Latest headline from thelincolnianonline.com: Bicara Therapeutics Shares Up 7.9 percent Whats Next |
Bicara Therapeutics Returns Distribution Density
The distribution of Bicara Therapeutics' historical returns is an attempt to chart the uncertainty of Bicara Therapeutics' future price movements. The chart of the probability distribution of Bicara Therapeutics daily returns describes the distribution of returns around its average expected value. We use Bicara Therapeutics Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bicara Therapeutics returns is essential to provide solid investment advice for Bicara Therapeutics.
| Mean Return | 0.44 | Value At Risk | -7.77 | Potential Upside | 8.54 | Standard Deviation | 5.92 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bicara Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bicara Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bicara Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bicara Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bicara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.42 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 5.87 | |
Ir | Information ratio | 0.05 |
Bicara Therapeutics Volatility Alert
Bicara Therapeutics Common exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bicara Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bicara Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bicara Therapeutics Fundamentals Vs Peers
Comparing Bicara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bicara Therapeutics' direct or indirect competition across all of the common fundamentals between Bicara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bicara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bicara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bicara Therapeutics to competition |
| Fundamentals | Bicara Therapeutics | Peer Average |
| Current Valuation | 577.25 M | 16.62 B |
| Shares Outstanding | 54.39 M | 571.82 M |
| Shares Owned By Insiders | 0.42 % | 10.09 % |
| Number Of Shares Shorted | 2.07 M | 4.71 M |
| Price To Book | 2.15 X | 9.51 X |
| EBITDA | (58.3 M) | 3.9 B |
| Total Debt | 382.75 M | 5.32 B |
| Book Value Per Share | (5.10) X | 1.93 K |
| Earnings Per Share | (3.75) X | 3.12 X |
| Market Capitalization | 1.1 B | 19.03 B |
| Total Asset | 233.98 M | 29.47 B |
| Retained Earnings | (153.02 M) | 9.33 B |
| Working Capital | 215.99 M | 1.48 B |
| Net Asset | 233.98 M |
Note: Discretionary transaction by Tpg Gp A, Llc of 1960425 shares of Bicara Therapeutics subject to Rule 16b-3 [view details]
Bicara Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bicara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Bicara Therapeutics Buy or Sell Advice
When is the right time to buy or sell Bicara Therapeutics Common? Buying financial instruments such as Bicara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bicara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Commodities Funds Thematic Idea Now
Commodities Funds
Funds or Etfs investing in commodities such as oil, gold, corn, soy, and agricultural goods. The Commodities Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Commodities Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.